This new report predicts that the world market for pharmaceutical wholesale and distribution activities will reach $747 bn for 2014. That revenue forecast appears in Pharma Wholesale and Distribution Market: World Outlook 2012-2022, published in June 2012.
The pharma industry and its supply chain partners will increase revenues from 2012 to 2022. New products – novel small molecules, generics and biologics – will stimulate the pharma W&D market. Many opportunities for rising drug sales exist, with high, growing W&D revenues possible from 2012 to 2022. There will be increasing dependence on emerging countries, with their fast-rising drug sales. Developed countries hold promise too, the study notes.
Kritika Chaudhari, a pharmaceutical industry analyst, explains: “Growth in the global pharmaceutical wholesale and distribution market to 2022 will be driven by the ageing world population and increasing demand for medicines of all types.
“Pharmaceutical wholesalers and distributors play an important role in connecting drug manufacturers to final buyers. A number of blockbuster drugs are going off patent in the next few years, which will threaten revenue generation. Nevertheless, the worldwide wholesale and distribution market will continue to grow as a result of increasing demand for novel drugs.”
This report provides revenue forecasts to 2022 at world market, submarket, company and national level. It forecasts world sales for the following main submarkets:
• Original-branded drugs
• Generic drugs.
Research, data and analyses cover activities of McKesson, Cardinal Health, AmerisourceBergen, The PHOENIX Group and other companies, with revenue forecasts. The scope of the field widens, with organisations collaborating and expanding their businesses.
The study discusses business activities and commercial news, shows research interviews with external authorities and forecasts revenues in leading national markets. The work analyses the US, Japan, EU5 countries, Brazil, Russia, China and India.